MedTrace Logo

Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients

NCT01438229 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2019-02-05

Study results available
· View outcomes & findings →

Summary

This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.

Conditions

Interventions

DEVICE

St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)

Catheter-based RF ablation in renal artery

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Vasilias Papademetriou, MD · First Cardioligy Clinic, Hippokration Hospital, University of Athens, Greece

  • Konstantinos Tsioufis, MD · First Cardioligy Clinic, Hippokration Hospital, University of Athens, Greece

  • Stephen Worthley, MD · Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, Australia

  • Ian Meredith, MD · Monash Medical Centre, Melbourne, Australia

  • Derek Chew, MD · Flinders Medical Centre, Adelaide, AUSTRALIA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2012-09-30
Completion
2014-07-31

Countries

  • Australia
  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01438229 on ClinicalTrials.gov